Hyperthermia Blog

News and Opinions About Our Industry

Soft Tissue Sarcoma cancer study using hyperthermia

The link between increased longevity and hyperthermia treatment was considered a landmark study when it published in late 2018 in the Journal of the American Medical Association.

sennewald sts infographic

Recently, our partners at Sennewald Medizintechnik, caught up with renowned expert and cancer study co-author Professor Dr. Lars Lindner of Ludwig-Maximilians-Universität (LMU) in Munich to get a deeper understanding of the findings.

After examining over 30 Soft Tissue Sarcoma trials, Prof. Dr. Linder lists the top four significant findings:

  1. Doxorubicin-based chemotherapy is and remains the standard of care for soft tissue sarcomas.
  2. The benefit of chemotherapy has also been shown in the adjuvant situation in high-risk patients.
  3. Neoadjuvant therapy is preferable because it combats potential micrometastasis at the earliest possible time and improves operability.
  4. Regional hyperthermia improves the effectiveness of chemotherapy and leads to improved patient survival.

The complete interview is available on the Sennewald Medizintechnik April 2021 newsletter.